Ondansetrone Teva (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetrone Teva, is a serotonin 5-HT3 receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetrone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is indicated for nausea and vomiting prevention across several clinical pathways. - Chemotherapy‑induced nausea and vomiting: helps reduce the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: provides prophylactic control during radiotherapy sessions. - Post‑operative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related hyperemesis gravidarum (when other treatments are ineffective): assists in controlling severe vomiting episodes. - Adult and pediatric postoperative nausea: offers age‑appropriate dosing to manage postoperative symptoms.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional reduced bowel movements. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Injection site pain (if administered parenterally).

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with high intravenous doses. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals. - Vision changes: blurred vision or visual disturbances. - Severe constipation or intestinal obstruction.

When using Ondansetron, consider the following safety measures. - Cardiac monitoring: assess baseline ECG in patients with known cardiac disease. - Drug interactions: review concomitant medications that may prolong QT interval. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before therapy. - Pregnancy: use only if benefits outweigh potential risks. - Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, requiring attention to the interaction severity.

Major Interactions (Avoid): - Other QT‑prolonging drugs: concurrent use can increase risk of serious arrhythmias. - Apomorphine: may cause profound hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, fluconazole): may modestly increase plasma levels. - Certain anti‑emetics (e.g., dexamethasone, metoclopramide): may require dose adjustments. - Tricyclic antidepressants: may slightly raise QT interval. - Serotonergic agents (e.g., SSRIs, SNRIs): monitor for signs of serotonin syndrome. - Calcium channel blockers: potential additive effect on cardiac conduction.